← Leaderboards
Lewis H Romer
Johns Hopkins University
$4,668,241
Attributed
$8,222,296
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,222,296 · 10
By mechanism
UH3$3,169,398 · 1
R01$1,612,120 · 1
UG3$952,595 · 1
P60$822,493 · 1
R21$442,882 · 1
P50$392,480 · 1
Top collaborators
- Steven Herbert Abman4 shared
- Dan E Berkowitz4 shared
- Erika S. Berman-Rosenzweig4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Steven Herbert Abman$28,175,515
- David Alan Kass$45,555,857
- Erika S. Berman-Rosenzweig$2,160,271
- Reda E Girgis$1,518,752
- Dan E Berkowitz$6,149,594
Others in their field
Top investigators on “Human Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$294,443,261
- Lawrence Corey · Fred Hutchinson Cancer Center$212,638,156
- Larry Arthur$131,303,476
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$114,079,276
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
Research focus
Human TissueVascular EndotheliumLaboratory MouseCell AdhesionExtracellular Matrix ProteinsLaboratory RabbitMacrophageCytokineInflammationVideo MicroscopyCell Adhesion MoleculesCell ProliferationSiteEnzyme ActivityLifeBiological Signal TransductionGene ExpressionUniversitiesLungChild CareExtracellular MatrixFutureApoptosisChemotaxis
Grant awards (25)
1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension$652,233
UH3 · FY2025 · HL · contact PI
1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension$1,218,226
UH3 · FY2024 · HL · contact PI
1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension$1,298,939
UH3 · FY2023 · HL · contact PI
1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension$952,595
UG3 · FY2021 · HL · contact PI
Arginase II, A Novel Target in Atherosclerosis$401,800
R01 · FY2014 · HL
Arginase II, A Novel Target in Atherosclerosis$390,320
R01 · FY2013 · HL
Arginase II, A Novel Target in Atherosclerosis$410,000
R01 · FY2012 · HL
Arginase II, A Novel Target in Atherosclerosis$410,000
R01 · FY2011 · HL
Endothelial Progenitor Cells for Lung Repair$185,790
K18 · FY2008 · HL · contact PI
Core--Imaging /Histology$211,021
P01 · FY2007 · HL · contact PI
Endothelial Progenitor Cells for Lung Repair$182,454
K18 · FY2007 · HL · contact PI
FAK in E.coli Pathogenesis$199,319
R21 · FY2006 · AI · contact PI
Core--Imaging /Histology$109,677
P01 · FY2006 · HL · contact PI
FAK in E.coli Pathogenesis$243,563
R21 · FY2005 · AI
FAK SIGNALING IN VASCULAR INJURY$158,765
P60 · FY2002 · DE
FAK SIGNALING IN VASCULAR INJURY$158,765
P60 · FY2002 · DE
INFLAMMATORY CYTOKINE EFFECTS ON CELL ADHESION IN PULMONARY VASCULAR EPITHELIUM$196,240
P50 · FY2001 · HL
FAK SIGNALING IN VASCULAR INJURY$158,765
P60 · FY2001 · DE
FAK SIGNALING IN VASCULAR INJURY$229,415
P60 · FY2000 · DE
INFLAMMATORY CYTOKINE EFFECTS ON CELL ADHESION IN PULMONARY VASCULAR EPITHELIUM$196,240
P50 · FY2000 · HL
FAK SIGNALING IN VASCULAR INJURY$116,783
P60 · FY2000 · DE
INTEGRIN SIGNALLING IN VASCULAR ENDOTHELIUM$63,764
K08 · FY2000 · HL
INTEGRIN SIGNALLING IN VASCULAR ENDOTHELIUM$50,122
K08 · FY2000 · HL
FAK SIGNALING IN VASCULAR INJURY$13,888
F06 · FY2000 · TW
FAK SIGNALING IN VASCULAR INJURY$13,612
F06 · FY2000 · TW